This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Astrazeneca Ab. Active years: 2002-2011.
Location History:
- Shrewsbury, MA (US) (2002)
- Wilmington, DE (US) (2011)
Company Filing History:
Years Active: 2002-2011
Title: Dennis J McCarthy: Innovator in Pharmaceutical Compounds
Introduction
Dennis J McCarthy is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds for medical use. With a total of 2 patents, his work has the potential to impact the treatment of various diseases.
Latest Patents
Among his latest patents is a groundbreaking invention related to ligands, which are radioactive compounds designed for therapeutic applications. This patent details a compound formula that includes pharmaceutically-acceptable salts, enantiomers, and in vivo-hydrolysable precursors. It also encompasses pharmaceutical compositions and formulations that utilize these compounds for treating diseases, either alone or in combination with other therapeutically-active substances. Another significant patent focuses on the use of certain affinity NMDA antagonists as antidepressants, highlighting the potential of these pharmaceutical compounds as effective agents in treating depression.
Career Highlights
Dennis J McCarthy is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to further his research and development efforts in the pharmaceutical sector, contributing to innovative solutions for healthcare challenges.
Collaborations
Throughout his career, Dennis has collaborated with esteemed colleagues, including Peter Dorff and Mark A Smith. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to the development of impactful pharmaceutical solutions.
Conclusion
Dennis J McCarthy's contributions to the field of pharmaceuticals through his patents and work at AstraZeneca exemplify his commitment to advancing medical science. His innovative approaches to drug development continue to pave the way for new treatments and therapies.